We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
+$4.02M
Cap. Flow %
0.39%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 71.97%
2 Miscellaneous 15.76%
3 Technology 5.67%
4 Consumer Discretionary 2.57%
5 Industrials 2.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CPRX
101
DELISTED
Catalyst Pharmaceutical
CPRX
-730,557
Closed -$3.38M
DOV icon
102
Dover
DOV
$25.5B
-57,576
Closed -$5.56M
ENPH icon
103
Enphase Energy
ENPH
$4.76B
-70,000
Closed -$3.33M
IMUX icon
104
Immunic
IMUX
$141M
-10,000
Closed -$1.21M
KPTI icon
105
Karyopharm Therapeutics
KPTI
$40.6M
-26,189
Closed -$7.44M
LITS
106
Lite Strategy Inc
LITS
$35.4M
-20,500
Closed -$1.69M
NVO
107
Novo Nordisk
NVO
$191B
-800,000
Closed -$26.2M
PANW icon
108
Palo Alto Networks
PANW
$307B
-180,000
Closed -$6.89M
PFE icon
109
PUT
Pfizer
PFE
$158B
-1,054,000
Closed -$32.7M
SLNO
110
DELISTED
Soleno Therapeutics
SLNO
-82,245
Closed -$2.74M
SNDX icon
111
CALL
Syndax Pharmaceuticals
SNDX
$1.58B
-100,000
Closed -$1.48M
SPY icon
112
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$804B
-189,000
Closed -$58.3M
TVTX icon
113
Travere Therapeutics
TVTX
$6.1B
-250,000
Closed -$5.1M
VKTX icon
114
Viking Therapeutics
VKTX
$3.42B
-205,000
Closed -$1.48M
WIX icon
115
WIX.com
WIX
$3.34B
-37,588
Closed -$9.63M
XBI icon
116
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
-750,000
Closed -$84M
XFOR icon
117
X4 Pharmaceuticals
XFOR
$347M
-18,860
Closed -$5.27M
QTTB icon
118
Q32 Bio
QTTB
$323M
-36,607
Closed -$10M
ITCI
119
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-228,700
Closed -$5.87M
ISEE
120
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
-200,000
Closed -$1.02M
BLU
121
DELISTED
BELLUS Health Inc.
BLU
-97,805
Closed -$1.01M
TCRR
122
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
-30,000
Closed -$461K
AKUS
123
DELISTED
Akouos Inc
AKUS
-100,000
Closed -$2.25M
NEOS
124
DELISTED
Neos Therapeutics, Inc
NEOS
-950,311
Closed -$651K
ARYAU
125
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
-200,000
Closed -$4M

Similar funds

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management's Q3 2020 filing shows 39 new, 20 increased, 28 reduced and 30 closed positions. Its largest new stake was BioXcel Therapeutics: 16,831 shares worth $11.7M. The largest sale was Bristol-Myers Squibb, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.